Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors

J Steffel, TF Lüscher - Journal of Cardiovascular Medicine, 2009 - journals.lww.com
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic
diseases. Although effective under optimal conditions, several drawbacks are imminent to …
被引用次数：29 相关文章

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

J Steffel, TF Lüscher - Journal of cardiovascular medicine (Hagerstown …, 2009 - folia.unifr.ch
English Vitamin K antagonists are the mainstay in the prevention and treatment of
thromboembolic diseases. Although effective under optimal conditions, several drawbacks …
[PDF] archive.org

[PDF][PDF] Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors

J Steffel, TF Lüscher - Journal of Cardiovascular Medicine, 2009 - scholar.archive.org
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic
diseases. Although effective under optimal conditions, several drawbacks are imminent to …

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

J Steffel, TF Lüscher - Journal of cardiovascular medicine (Hagerstown …, 2009 - sonar.ch
English Vitamin K antagonists are the mainstay in the prevention and treatment of
thromboembolic diseases. Although effective under optimal conditions, several drawbacks …

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors

J Steffel, TF Lüscher - Journal of Cardiovascular Medicine, 2009 - zora.uzh.ch
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic
diseases. Although effective under optimal conditions, several drawbacks are imminent to …

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors

J Steffel, TF Lüscher - Journal of cardiovascular medicine …, 2009 - pubmed.ncbi.nlm.nih.gov
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic
diseases. Although effective under optimal conditions, several drawbacks are imminent to …

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

J Steffel, TF Lüscher - Journal of Cardiovascular Medicine …, 2009 - europepmc.org
Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic
diseases. Although effective under optimal conditions, several drawbacks are imminent to …